Lipella Pharmaceuticals News

Express News | Lipella Pharmaceuticals Expands Its Advisory Board to Include Oncology Expertise

Moomoo 24/7Apr 17 08:00 ET

Express News | Maxim Group Initiates Coverage On Lipella Pharmaceuticals With Buy Rating, Announces Price Target of $2

Moomoo 24/7Apr 9 11:36 ET

Lipella Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 185.92% Maxim Group → $2 Initiates Coverage On → Buy

BenzingaApr 9 11:35 ET

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant

GlobeNewswireApr 5 08:00 ET

Express News | Lipella Pharmaceuticals Announces FDA Type C Meeting For LP-10 For Hemorrhagic Cystitis; Co. Expects To Meet With FDA May 21

Moomoo 24/7Apr 3 08:02 ET

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with

GlobeNewswireApr 3 08:00 ET

Lipella Pharmaceuticals(LIPO.US) 10% Shareholder Buys US$45,451.5 in Common Stocks

$Lipella Pharmaceuticals(LIPO.US)$ 10% Shareholder Kaufman Jonathan H purchased 55,000 shares of Common Stocks on Mar 18, 19, 2024 at an average price of $0.8264 for a total value of $45,451.5.Source:

moomoo NewsMar 19 19:01 ET

PRISM MarketView Spotlights Lipella Pharmaceuticals as It Seizes Opportunities in Rare Disease

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals' CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory

GlobeNewswireMar 7 15:23 ET

EYEN, BYSI and FENG Among Mid-day Movers

Seeking AlphaMar 5 12:38 ET

Regenxbio, Quoin Pharmaceuticals, Renalytix Among Healthcare Movers

Seeking AlphaMar 5 10:02 ET

QTI, RNLX and MTC Among Pre-market Losers

Seeking AlphaMar 5 08:31 ET

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersSunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 55.9% to $0.07 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.8 million. CASI Pharmaceuticals

BenzingaMar 5 08:09 ET

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant

GlobeNewswireMar 5 08:00 ET

SMR, BBAI and PHUN Are Among Pre Market Gainers

Seeking AlphaMar 4 08:34 ET

Lipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 Loss per Share (Vs US$0.64 Loss in FY 2022)

Yahoo FinanceMar 1 06:18 ET

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (NASDAQ:LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company,

GlobeNewswireFeb 20 08:00 ET

Lipella Pharmaceuticals Marks Successful First Year With Strategic Progress and Key Milestones Accomplished

Lipella Granted Two Orphan Drug Designations by FDAPITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering,

GlobeNewswireDec 20, 2023 08:00 ET

Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella Pharmaceuticals, Allergan, Ironwood Pharmaceuticals, Vaneltix Pharma, Prevail Infoworks

New York, USA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella Pharmaceuticals,

GlobeNewswireDec 13, 2023 13:00 ET

Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts

US stocks looked set to open lower Friday as investors parsed strong employment data and awaited reports on University of Michigan consumer sentiment and the Baker Hughes North American rig count. Dow

MT NewswiresDec 8, 2023 09:23 ET

Top Premarket Decliners

Cyngn (CYN) shares fell 39% premarket on Friday, after soaring 64% in the previous session. Applied UV (AUVI) shares sank 26%, after saying it will effect a 1-for-25 reverse stock split of its common

MT NewswiresDec 8, 2023 07:46 ET